Ergoteles’s Cytek Biosciences CTKB Stock Holding History

Ergoteles’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-177,001	Closed	-$2.89M	–	1292
2021 Q4	$2.89M	Buy	+177,001	New	+$3.71M	0.11%	191

Other funds holding CTKB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MGM

Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ergoteles's CTKB Position: Q1 2022 in Review

Ergoteles sold out of Cytek Biosciences (CTKB) in Q1 2022, closing a stake of 177,001 shares — an estimated $2.89M sold.

Ergoteles first reported a position in CTKB in Q4 2021 and held it in 1 quarter. The position peaked at $2.89M in Q4 2021. 74 funds tracked by Wall St. Rank hold CTKB as of Q1 2022.

Ergoteles reported no remaining Cytek Biosciences position as of Q1 2022 after selling out during the quarter.
Ergoteles sold 177,001 Cytek Biosciences shares in Q1 2022, an estimated $2.89M.
Ergoteles first reported a position in Cytek Biosciences in Q4 2021 and held it in 1 quarter.
Ergoteles's Cytek Biosciences position peaked at $2.89M in Q4 2021.
74 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2022.

Based on Ergoteles's 13F filing for Q1 2022, filed 13 May 2022.